Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FORADIL CERTIHALER vs AEROLONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Formoterol is a long-acting beta2-adrenergic receptor agonist that stimulates intracellular adenyl cyclase, increasing cyclic AMP production and causing bronchodilation.
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Long-term maintenance treatment of asthma,Prevention of exercise-induced bronchospasm,Maintenance treatment of chronic obstructive pulmonary disease (COPD)
Treatment of bronchospasm in patients with COPD,Long-term maintenance treatment of asthma
One inhalation (12 mcg) twice daily via oral inhalation.
AEROLONE is not a recognized drug; no standard dosing available.
The terminal elimination half-life of formoterol (active component) ranges from 5 to 10 hours following inhalation. This supports twice-daily dosing, though clinical effect may persist longer due to prolonged receptor binding.
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Formoterol is extensively metabolized by direct glucuronidation via UGT1A1, UGT1A3, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT2B7, and UGT2B15, and O-demethylation via CYP2D6 and CYP2C19.
Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites.
After oral inhalation, the majority of a dose is excreted in feces (up to 70%) as unchanged drug and metabolites via biliary elimination. Renal excretion accounts for approximately 13-25% of the dose, primarily as metabolites. Unabsorbed drug accounts for the remainder.
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
Formoterol is approximately 60-70% bound to plasma proteins (primarily albumin).
Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein.
The volume of distribution (Vd) of formoterol is approximately 3.4 L/kg, indicating extensive distribution into tissues beyond plasma.
3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding.
Inhaled bioavailability is highly variable, approximately 20-30% of the inhaled dose reaches the lungs. Oral bioavailability is low (<10%) due to first-pass metabolism. The swallowed portion contributes minimally to systemic levels.
Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%.
No dosage adjustment required for renal impairment. Use with caution in severe impairment.
No data; not applicable.
No dosage adjustment recommended; pharmacokinetics unaffected by mild to moderate hepatic impairment.
No data; not applicable.
For children 5 years and older: one inhalation (12 mcg) twice daily. Safety and efficacy in children under 5 not established.
No data; not applicable.
No specific dose adjustment; monitor for adverse effects due to potential age-related comorbidities.
No data; not applicable.
Long-acting beta2-adrenergic agonists increase the risk of asthma-related death; Foradil should only be used as add-on therapy for patients not adequately controlled on other asthma controllers or whose disease severity warrants initiation of a LABA.
None
Asthma-related death,Deterioration of disease,Use of anti-inflammatory agents,Paradoxical bronchospasm,Cardiovascular effects,Hypokalemia,Hyperglycemia,Immediate hypersensitivity reactions
Paradoxical bronchospasm,Cardiovascular effects (e.g., increased heart rate, QT prolongation),Hypokalemia,Hyperglycemia
Treatment of status asthmaticus or other acute episodes of asthma,Hypersensitivity to formoterol fumarate or any inactive ingredients
Hypersensitivity to arformoterol or any component of the formulation
No known food interactions. Formoterol may increase blood glucose, so monitor if diabetic. Avoid high-fat meals if using with certain devices? Not applicable.
No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component.
Formoterol fumarate (FORADIL CERTIHALER) is classified as FDA Pregnancy Category C. In animal studies, formoterol caused fetal malformations (e.g., omphalocele, skeletal abnormalities) at high systemic exposures. There are no adequate well-controlled studies in pregnant women. Risk to fetus cannot be ruled out; use only if potential benefit justifies potential risk. First trimester: limited data, theoretical risk based on animal findings. Second and third trimesters: may cause uterine relaxation and delay labor; avoid use near term unless clearly needed.
No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure.
It is unknown if formoterol is excreted in human breast milk. No M/P ratio available. In lactating rats, formoterol was detected in milk. Because many drugs are excreted in human milk, caution is advised. Decision to discontinue nursing or drug should consider importance of drug to mother. Consider alternative therapies with more breastfeeding safety data.
Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation).
No specific dose adjustments recommended for pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may reduce systemic exposure, but standard dosing is generally maintained. Use lowest effective dose to control asthma. Avoid use during labor and delivery due to tocolytic effect.
No specific dose adjustment required based on pharmacokinetic changes; pregnancy may cause decreased airway reactivity but no significant changes in fluticasone clearance. Maintain lowest effective dose to control asthma. No dose increase recommended solely due to pregnancy. Monitor asthma control and adjust dose as per standard guidelines.
Formoterol is a long-acting beta-agonist (LABA) with rapid onset (within 5 minutes). Must not be used as monotherapy for asthma without concomitant inhaled corticosteroid. Do not use for acute bronchospasm; short-acting beta-agonists are preferred. Rinse mouth after inhalation to prevent thrush and hoarseness. Monitor for paradoxical bronchospasm, tachyphylaxis, and cardiovascular effects. Can be used once or twice daily depending on formulation.
AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing.
Do not use Foradil Certihaler to relieve sudden breathing problems; always have a rescue inhaler (e.g., albuterol) available.,Use exactly as prescribed; do not skip doses or use more than prescribed.,Rinse your mouth with water after each use to prevent mouth infection and hoarseness.,Tell your doctor if you have heart problems, high blood pressure, seizures, or thyroid disease.,If asthma, always use this medication with an inhaled corticosteroid; never use LABA alone.,Seek medical help if your symptoms worsen or rescue inhaler does not work well.,Store at room temperature away from moisture and heat. Keep cap on when not in use.
Use AEROLONE exactly as prescribed; do not exceed recommended dose.,Rinse your mouth with water after each use (do not swallow) to prevent thrush.,This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you.,Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing.,Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FORADIL CERTIHALER vs AEROLONE, answered by our medical review team.
FORADIL CERTIHALER is a Bronchodilator that works by Formoterol is a long-acting beta2-adrenergic receptor agonist that stimulates intracellular adenyl cyclase, increasing cyclic AMP production and causing bronchodilation.. AEROLONE is a Bronchodilator that works by Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FORADIL CERTIHALER and AEROLONE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FORADIL CERTIHALER is: One inhalation (12 mcg) twice daily via oral inhalation.. The standard adult dose of AEROLONE is: AEROLONE is not a recognized drug; no standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FORADIL CERTIHALER and AEROLONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FORADIL CERTIHALER is classified as Category C. Formoterol fumarate (FORADIL CERTIHALER) is classified as FDA Pregnancy Category C. In animal studies, formoterol caused fetal malformations (e.g., omphalocele, skeletal abnormalit. AEROLONE is classified as Category C. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled stu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.